On June 29, 2021 Cancer Targeted Technology (CTT), a privately held Seattle-based biotechnology company, reported that it received a milestone payment from Advanced Accelerator Applications International S.A. (AAA), a Novartis company, triggered by the upcoming clinical trials of investigational 18F-CTT1057, a diagnostic PET imaging agent for prostate cancer (Press release, Cancer Targeted Technology, JUN 29, 2021, View Source [SID1234584483]). CTT1057 targets the biomarker, Prostate Specific Membrane Antigen (PSMA), which is over-expressed on most prostate cancer cells. Prior to licensing, CTT completed prostate cancer clinical trials of CTT1057 in adult males at University of California, San Francisco (UCSF), with encouraging safety and imaging results. Based on this clinical data, binding characteristics of the molecule, and solid patent protection, CTT1057 was licensed to AAA to undergo further development in the upcoming GuidePath and GuideView clinical studies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This licensing deal with AAA is an important collaboration for CTT and we are very excited to see CTT1057 moving forward as a potential new imaging agent for prostate cancer," stated Dr. Beatrice Langton-Webster, CTT’s Chief Executive Officer. The milestone payments, along with an NIH SBIR Phase IIB grant, are the key assets that CTT is using to advance its new radiolabeled small molecule drug CTT1403, a companion radiotherapeutic to CTT1057. Features that make the phosphoramidate PSMA-binding scaffold unique include irreversible binding to PSMA and excellent uptake by PSMA-expressing tumor cells. CTT1057 and CTT1403 are a theranostic pair that can both diagnose and treat solid tumors that express PSMA and are being studied together in the current CTT1403 therapeutic clinical trial (NCT03822871) that CTT is conducting with lead investigator Dr. Rahul Aggarwal at UCSF. The unique chemical structures of CTT’s drugs were conceived by Dr. Cliff Berkman, Professor of Chemistry at Washington State University (WSU).

On June 29, 2021 Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology that enables antibody-drug conjugates (ADCs) with best-in-class therapeutic index, reported the signing of a non-exclusive, target-specific license agreement with Innovent Biologics Inc., a leading biopharmaceutical company developing innovative medicines for the treatment of major diseases (Press release, Synaffix, JUN 29, 2021, View Source [SID1234584482]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of the agreement, Synaffix will provide all the necessary proprietary ADC technologies including GlycoConnect, HydraSpace and one of its toxSYN linker-payloads, to enable Innovent to rapidly progress one of its antibodies as a best-in-class ADC candidate. The deal is the culmination of a successful initial proof-of-concept research period between the companies.

Upon signature, Innovent is granted the rights to deploy the above ADC technologies for one therapeutic molecule. Innovent will be responsible for the research, development, manufacturing and commercialization of the ADC product. Synaffix will closely support Innovent’s research activities and will be responsible for manufacturing components that are specifically related to its proprietary technologies.

Synaffix is eligible to receive an upfront payment, milestone payments related to certain development and sales performance achievements, as well as royalties on potential future commercial sales of the ADC product.

Dr. Yongjun Liu, President of Innovent said:

"We are excited to collaborate with Synaffix as Innovent is expanding its pipeline into the ADC space. Our collaboration with Synaffix adds a promising new ADC candidate to our preclinical pipeline through leveraging Synaffix’s validated, differentiated and innovative ADC technology platform and Innovent’s strong antibody capabilities. Based on Synaffix’s seamless partnering model, we could rapidly combine Synaffix’s ADC technologies with Innovent’s antibody, generate compelling research data and keep moving the project ahead swiftly."

Peter van de Sande, CEO of Synaffix said:

"This is the fourth commercial licensing deal that illustrates the potential of the Synaffix platform to increase the competitive position of our partners within the ADC space. Innovent is an ideal partner for Synaffix due to its strategic focus on innovative medicines and strong R&D capability for high quality biologic drugs. We look forward to working closely together on this exciting development program."

"Central to enhancing our value proposition has been the addition of multiple new proprietary linker-payloads to our ADC technology portfolio. In addition to our well-understood, clinical-stage technologies, GlycoConnect and HydraSpace, our proprietary toxSYN linker-payload platform facilitates any company with an antibody to develop its own highly-competitive ADC."

About The Synaffix ADC Platform Technology
Synaffix’s proprietary ADC technology platform consists of GlycoConnect, HydraSpace and toxSYN linker-payload technologies. Both GlycoConnect and HydraSpace are clinical-stage technologies that enable best-in-class ADCs with significantly enhanced efficacy and tolerability.

GlycoConnect is a conjugation technology that exploits the native antibody glycan for site-specific and stable payload attachment and is tunable to DAR1, DAR2 or DAR4 formats.

HydraSpace is a compact and highly polar spacer technology that is designed to further enhance therapeutic index, particularly with hydrophobic payloads.

toxSYN is a platform of multiple unique linker-payloads that span key, validated mechanisms-of-action for ADC product development.

The combination of these three technologies provides developers with a "one stop" and easy-to-use ADC technology platform, allowing any antibody developer to develop its own proprietary ADC and any ADC developer to expand its pipeline further and increase its competitive position.

In September 2020, Synaffix was recognized with first place in the "Best ADC Platform Technology" award category at the World ADC Awards ceremony following a global review of technologies, voting by industry peers and final evaluation by a panel of independent industry experts.

On June 29, 2021 Takeda Pharmaceutical Company Limited ("Takeda") (TSE:4502/NYSE:TAK) reported that it has filed its Annual Report on Form 20-F for the fiscal year ended March 31, 2021 (the "Annual Report") with the U.S. Securities and Exchange Commission (the "SEC") (Press release, Takeda, JUN 29, 2021, View Source [SID1234584481]). Takeda filed the Annual Report with the SEC on June 29, 2021, and the Annual Report can be accessed on Takeda’s website at: View Source

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In addition, Takeda will also provide a hard copy of the Annual Report, which includes its most recent complete audited financial statements free of charge to any shareholder upon request. Please contact Takeda Investor Relations by e-mail at [email protected].

Additionally, Takeda also published today its 2021 Annual Integrated Report for the fiscal year ended March 31, 2021. It can be accessed on Takeda’s website at: View Source

On June 29, 2021 4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, reported that Duncan Peyton, Chief Executive Officer, and Alex Stevenson, Chief Scientific Officer, will present a corporate overview followed by a fireside chat at the virtual Ladenburg Thalmann Healthcare Conference on Tuesday, July 13, 2021, at 2:30pm ET (7:30pm BST) (Press release, 4d Pharma, JUN 29, 2021, View Source [SID1234584480]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A webcast of the presentation will be available via the ‘Events’ section of the 4D pharma website at www.4dpharmaplc.com. An archived replay of the webcast will be available for 90 days following the presentation.

On June 29, 2021 Exicure, Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA) technology, reported that CEO David Giljohann will present a company update as well as participate in a series of 1×1 meetings at the Ladenburg Thalmann 2021 Healthcare Conference occurring July 13-14, 2021 (Press release, Exicure, JUN 29, 2021, View Source [SID1234584479]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Date: July 13, 2021
Presentation Time: 1:00-1:25 PM in Track One
Location: The panel discussion will be webcast (available here)

Replays of the presentation will be available on Exicure’s website for 30 days following the presentation.